<DOC>
	<DOCNO>NCT01691625</DOCNO>
	<brief_summary>The purpose study show adoptive cellular therapy autologous dendritic cell cytokine-induced killer cell ( CIK ) combine concurrent chemoradiation could improve quality life patient locally advanced esophageal cancer , compare concurrent chemoradiation .</brief_summary>
	<brief_title>Concurrent Chemoradiation With Without DC-CIK Immunotherapy Treating Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>cytologically histologically confirm locally advanced esophageal carcinoma Age : &gt; 18 Karnofsky performance status ≥ 70 At least one measurable tumor lesion accord RECIST criterion . Normal function heart , lung , liver , kidney bone marrow Blood exam qualify chemotherapy , include hemoglobulin ≥9 g/dl , neutrophil ≥1.5×109/L platelet ( PLT ) ≥100×109/L , creatinine ≤1.5 UNL Informed consent sign Patients metastatic disease central nervous system ( CNS ) . Patients pregnant nursing . Patients poor bone marrow , liver kidney function , would make chemotherapy intolerable Patients contraindication irradiation : complete obstruction esophagus , deep esophageal ulcer , fistula mediastinum , haematemesis coexist morbidity investigator believe suitable chemoradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Locally advanced esophageal carcinoma</keyword>
	<keyword>DC-CIK</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>